Know Cancer

forgot password

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

Open (Enrolling)

Thank you

Trial Information

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

In this protocol, we plan to identify specific markers from nuclear magnetic resonance
(NMR)biochemical and molecular genetic analysis that predict clinical outcome and
responsiveness to therapy in patients with soft tissue sarcoma. Although most sarcomas
rarely present diagnostic dilemmas because each has consistent morphologic and cytogenetic
features that can readily be identified, it is not possible with conventional methods to
predict what the clinical outcome will be for each individual patient, or how a given tumor
will respond to neoadjuvant therapy. Thus,new methods for assessing the potential of these
tumors to recur or metastasize and respond to therapy will result in real benefits for
patients with these sarcomas.

Inclusion Criteria:

- All patients with known or suspected sarcoma who will have or have had tissue removed
for therapeutic or diagnostic purposes.

- Patients will be entered without preference for any particular racial/ethnic group or

- Patients may have received prior hormonal therapy, cytotoxic chemotherapy,
irradiation, immunotherapy or surgical therapy.

- Tissue specimens must be large enough in quantity to allow routine pathologic
analysis, with the research laboratory specimen removed from the residual specimen,
which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core
biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma
specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue -
0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts
for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3
mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or
muscle tissue - 30 mg (three 3 x 3 x 3 mm cube

Exclusion Criteria:

- None

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Analyze NMR biochemical and molecular patterns from oligonucleotide, SNP and CGH arrays to identify markers that can provide an objective measure of sarcoma differentiation, cellularity, proliferation, necrosis and apoptosis.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Singer Singer, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

June 2002

Completion Date:

June 2014

Related Keywords:

  • Sarcoma
  • Biochemical Determinants
  • Molecular Determinants
  • Sarcoma



Memorial Sloan-Kettering Cancer Center New York, New York  10021